Αρχική World News FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic, Hormone Receptor-positive, HER2-negative Breast... World News FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic, Hormone Receptor-positive, HER2-negative Breast Cancer Από Ogkologos - 27 Φεβρουαρίου, 2025 570 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TROPION-Breast01 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Improving Care for Underserved People With Cancer and Evaluating Delays in... 20 Σεπτεμβρίου, 2021 Biopsie: 5 lucruri pe care fiecare pacient trebuie să le cunoască 18 Μαΐου, 2021 Man Born Without Legs Proves He’s Greater Than Any Obstacle He’s... 5 Δεκεμβρίου, 2021 ESMO Breast Cancer 2025, Munich, Germany, 14-17 May 2025 7 Μαΐου, 2025 Φόρτωση περισσοτέρων HOT NEWS Speaking with One Cancer Voice for cancer patients in England Combination of Azacitidine and Venetoclax in Previously Untreated AML Research with integrity – all the fun of the FAIR Cancer in My Community: How People With Cancer Access Care in...